You are here

Clinical Trials: Cord Blood

Conditions:   Acute Myeloid Leukemia;   Leukemia, Lymphoblastic, Acute;   Leukemia, Bilineage, Acute;   Leukemia, Myeloid, Chronic
Intervention:   Biological: Ex vivo expansion of cord blood
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Children's Cancer Foundation
Condition:   Graft Versus Host Disease
Intervention:   Drug: Interleukin-2
Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Novartis
Active, not recruiting
Conditions:   Myelodysplastic Syndrome;   Leukemia
Interventions:   Procedure: Cord Blood Infusion;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Rituximab;   Other: ATG;   Drug: Cyclophosphamide;   Drug: Clofarabine;   Radiation: Total Body Irradiation (TBI);   Drug: Melphalan;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: G-CSF
Sponsors:   M.D. Anderson Cancer Center;   ViaCell;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
Condition:   Epidermolysis Bullosa
Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: hematopoietic bone marrow transplantation
Sponsor:   Masonic Cancer Center, University of Minnesota
Condition:   Inherited Immune Deficiencies
Interventions:   Drug: Fludarabine;   Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine;   Drug: Sirolimus or equivalent based on response;   Drug: Granulocyte Colony Stimulating Factor (G-CSF);   Other: hematopoietic progenitor cells
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 1, 2016
Conditions:   Sickle Cell Disease;   Beta Thalassemia
Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Alemtuzumab;   Procedure: Allogeneic stem cell transplant
Sponsor:   Columbia University
Recruiting - verified July 2017
Condition:   Hodgkin's Disease
Interventions:   Drug: Gemcitabine;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Antithymocyte Globulin;   Procedure: Allogeneic Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Filgrastim (G-CSF);   Drug: Methotrexate
Sponsor:   M.D. Anderson Cancer Center
Conditions:   B-cell Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Graft Versus Host Disease;   L1 Childhood Acute Lymphoblastic Leukemia;   L2 Childhood Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia
Interventions:   Drug: thiotepa;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: methotrexate;   Drug: sirolimus;   Radiation: total body irradiation
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Conditions:   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Secondary Myelofibrosis
Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: Treg cell infusion;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsor:   Masonic Cancer Center, University of Minnesota
Conditions:   Breast Cancer;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Drug: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: radiation therapy;   Procedure: umbilical cord blood transplantation
Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)